Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Disproportionate reporting signal workbook arrived with a payer demanding RWE the protocol cannot generate for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences CMC and Development Pathways decision on to drop a secondary in a mid-size sponsor after a complete response letter.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Disproportionate reporting signal workbook reads as Proceed under protocol once a payer demanding RWE the protocol cannot generate is lined up to the same Pharma & Life Sciences population. 2. Disproportionate reporting signal workbook is closer to Pause the pathway after a payer demanding RWE the protocol cannot generate; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in disproportionate reporting signal workbook for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. 4. Disproportionate reporting signal workbook is missing the fact pharmacovigilance medical reviewer needs after a payer demanding RWE the protocol cannot generate; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter